Skip to main content

Advertisement

SpringerLink
Log in

Issues of concern in risk assessment, genetic counseling, and genetic testing of younger breast cancer patients in Japan

  • Special Feature
  • Breast cancer in young women: Issues and perspectives regarding patients' and survivors' care
  • Published:
Breast Cancer Aims and scope Submit manuscript

Abstract

About 5–10 % of breast cancer cases are considered to be hereditary, and germ line mutations in the BRCA1 and BRCA2 genes have been proven to contribute to the development of hereditary breast and/or ovarian cancer syndrome (HBOC). Breast cancer diagnosed at a young age is an indication of a higher likelihood of HBOC. Risk assessment, genetic counseling, and BRCA1/BRCA2 mutation testing, especially for younger women with breast cancer, have started to be an integral element of practice due to advances in gene sequencing technologies and accumulating evidence for the clinical implications of BRCA mutation status for not only early breast cancer management, but also for the patient’s own and their family’s next cancer risk, and proactive steps toward a risk-reducing approach. As yet, the cancer genetic service system is immature in Japan. There are several problems to be solved to improve cancer genetic services in clinical practice for breast cancer.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Center for Cancer Control and Information Services NCC, Japan. Cancer statistics in Japan. http://ganjoho.ncc.go.jp/public/statistics/index.html (cited 1 Jan 2013).

  2. Fackenthal JD, Olopade OI. Breast cancer risk associated with BRCA1 and BRCA2 in diverse populations. Nat Rev Cancer. 2007;12:937–48.

    Article  Google Scholar 

  3. National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology. Genetic/familial high-risk assessment: breast and ovarian; 2012, http://www.nccn.org/index.asp.

  4. Ruddy KJ, Gelber S, Shin J, Garber JE, Rosenberg R, Przypysny M, et al. Genetic testing in young women with breast cancer: results from a web-based survey. Ann Oncol. 2009;21:741–7.

    Article  PubMed  Google Scholar 

  5. US Preventive Services Task Force. Genetic risk assessment and BRCA mutation testing for breast and ovarian cancer susceptibility: recommendation statement. Ann Intern Med. 2005;143:355–61.

    Article  Google Scholar 

  6. Antoniou AC, Hardy R, Walker L, Evans DG, Shenton A, Eeles R, et al. Predicting the likelihood of carrying a BRCA1 or BRCA2 mutation: validation of BOADICEA, BRCAPRO, IBIS, Myriad and the Manchester scoring system using data from UK genetics clinics. J Med Genet. 2008;45:425–31.

    Article  PubMed  CAS  Google Scholar 

  7. Riley BD, Culver JO, Skrzynia C, Senter LA, Peters JA, Costalas JW, et al. Essential elements of genetic cancer risk assessment, counseling, and testing: updated recommendations of the National Society of Genetic Counselors. J Genet Couns. 2012;21:151–61.

    Article  PubMed  Google Scholar 

  8. Berliner JL, Fay AM, Cummings SA, Burnett B, Tillmanns T. NSGC practice guideline: risk assessment and genetic counseling for hereditary breast and ovarian cancer. J Genet Couns. 2013;22:155–63.

    Article  PubMed  Google Scholar 

  9. Bellcross CA, Kolor K, Goddard KAB, Coates RJ, Reyes M, Khoury MJ. Awareness and utilization of BRCA1/2 testing among U.S. primary care physicians. Am J Prev Med. 2011;40:61–6.

    Article  PubMed  Google Scholar 

  10. Trivers KF, Baldwin LM, Miller JW, Matthews B, Andrilla CH, Lishner DM, et al. Reported referral for genetic counseling or BRCA 1/2 testing among United States physicians: a vignette-based study. Cancer. 2011;117:5334–43.

    Article  PubMed  Google Scholar 

  11. Zilliacus E, Meiser B, Gleeson M, Watts K, Tucker K, Lobb EA, et al. Are we being overly cautious? A qualitative inquiry into the experiences and perceptions of treatment-focused germline BRCA genetic testing amongst women recently diagnosed with breast cancer. Support Care Cancer. 2012;20:2949–58. doi:10.1007/s00520-012-1427-6.

    Article  PubMed  CAS  Google Scholar 

  12. Tung N. Management of women with BRCA mutations: a 41-year-old woman with a BRCA mutation and a recent history of breast cancer. JAMA. 2011;305:2211–20.

    Article  PubMed  CAS  Google Scholar 

  13. Pierce LJ, Phillips K-A, Griffith KA, Buys S, Gaffney DK, Moran MS, et al. Local therapy in BRCA1 and BRCA2 mutation carriers with operable breast cancer: comparison of breast conservation and mastectomy. Breast Cancer Res Treat. 2010;121:389–98.

    Article  PubMed  PubMed Central  Google Scholar 

  14. Evans DGR, Moran A, Hartley R, Dawson J, Bulman B, Knox F, et al. Long-term outcomes of breast cancer in women aged 30 years or younger, based on family history, pathology and BRCA1/BRCA2/TP53 status. Br J Cancer. 2010;102:1091–8.

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  15. Metcalfe K, Gershman S, Lynch HT, Ghadirian P, Tung N, Kim-Sing C, et al. Predictors of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers. Br J Cancer. 2011;104:1384–92.

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  16. Heemskerk-Gerritsen B. Is risk-reducing mastectomy in BRCA1/2 mutation carriers with a history of unilateral breast cancer beneficial with respect to distant disease-free survival and overall survival [abstract]? Eur J Cancer. 2010;8:s206.

    Article  Google Scholar 

  17. Tutt A, Robson M, Garber JE, Domchek SM, Audeh MW, Weitzel JN, et al. Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial. Lancet. 2010;376:235–44.

    Article  PubMed  CAS  Google Scholar 

  18. Chionh F, Mitchell G, Lindeman GJ, Friedlander M, Scott CL. The role of poly adenosine disphosphate ribose polymerase inhibitors in breast and ovarian cancer: current status and future directions. Asia Pac J Clin Oncol. 2011;7:197–211.

    Article  PubMed  Google Scholar 

  19. Hedenfalk I, Duggan D, Chen Y, Radmacher M, Bittner M, Simon R, et al. Gene-expression profiles in hereditary breast cancer. N Engl J Med. 2001;344:539–48.

    Article  PubMed  CAS  Google Scholar 

  20. Armes JE, Trute L, White D, Southey MC, Hammet F, Tesoriero A, et al. Distinct molecular pathogeneses of early-onset breast cancers in BRCA1 and BRCA2 mutation carriers: a population-based study. Cancer Res. 1999;59:2011–7.

    PubMed  CAS  Google Scholar 

  21. Livasy CA, Karaca G, Nanda R, Tretiakova MS, Olopade OI, Moore DT, et al. Phenotypic evaluation of the basal-like subtype of invasive breast carcinoma. Mod Pathol. 2006;19:264–71.

    Article  PubMed  CAS  Google Scholar 

  22. Kwon JS, Gutierrez-Barrera AM, Young D, Sun CC, Daniels MS, Lu KH, et al. Expanding the criteria for BRCA mutation testing in breast cancer survivors. J Clin Oncol. 2010;28:4214–20.

    Article  PubMed  Google Scholar 

  23. Mavaddat N, Barrowdale D, Andrulis IL, Domchek SM, Eccles D, Nevanlinna H, et al. Pathology of breast and ovarian cancers among BRCA1 and BRCA2 mutation carriers: results from the Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA). Cancer Epidemiol Biomarkers Prev. 2012;21:134–47.

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  24. Klee E, Hoppman-Chaney N, Ferber M. Expanding DNA diagnostic panel testing: is more better? Expert Rev. Mol Diagn. 2011;11:703–9.

    CAS  Google Scholar 

  25. Chen S, Parmigiani G. Meta-analysis of BRCA1 and BRCA2 penetrance. J Clin Oncol. 2007;25:1329–33.

    Article  PubMed  PubMed Central  Google Scholar 

  26. McDonnell SK, Schaid DJ, Myers JL, Grant CS, Donohue JH, Woods JE, et al. Efficacy of contralateral prophylactic mastectomy in women with a personal and family history of breast cancer. J Clin Oncol. 2001;19:3938–43.

    PubMed  CAS  Google Scholar 

  27. Herrinton LJ, Barlow WE, Yu O, Geiger AM, Elmore JG, Barton MB, et al. Efficacy of prophylactic mastectomy in women with unilateral breast cancer: a cancer research network project. J Clin Oncol. 2005;23:4275–86.

    Article  PubMed  Google Scholar 

  28. Domchek SM, Friebel TM, Singer CF, Evans DG, Lynch HT, Isaacs C, et al. Association of risk-reducing surgery in BRCA1 or BRCA2 mutation carriers with cancer risk and mortality. JAMA. 2010;304:967–75.

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  29. Kauff ND, Domchek SM, Friebel TM, Robson ME, Lee J, Garber JE, et al. Risk-reducing oophorectomy for the prevention of BRCA1- and BRCA2-associated breast and gynecologic cancer: a multicenter, prospective study. J Clin Oncol. 2008;26:1331–7.

    Article  PubMed  PubMed Central  Google Scholar 

  30. Tuttle TM, Habermann EB, Grund EH, Morris TJ, Virnig BA. Increasing use of contralateral prophylactic mastectomy for breast cancer patients: a trend toward more aggressive surgical treatment. J Clin Oncol. 2007;25:5203–9.

    Article  PubMed  Google Scholar 

  31. Metcalfe KA, Lubinski J, Ghadirian P, Lynch H, Kim-Sing C, Friedman E, Hereditary Breast Cancer Clinical Study Group, et al. Predictors of contralateral prophylactic mastectomy in women with a BRCA1 or BRCA2 mutation: the Hereditary Breast Cancer Clinical Study Group. J Clin Oncol. 2008;26:1093–7.

    Article  PubMed  Google Scholar 

  32. Weitzel JN, Blazer KR, Macdonald DJ, Culver JO, Offit K. Genetics, genomics, and cancer risk assessment: state of the art and future directions in the era of personalized medicine. CA Cancer J Clin. 2011. doi:10.3322/caac.20128.

    PubMed  PubMed Central  Google Scholar 

  33. Bowen D, McTiernan A, Burke W, Powers D, Pruski J, Durfy S, et al. Participation in breast cancer risk counseling among women with a family history. Cancer Epidemiol Biomarkers Prev. 1999;8:581–5.

    PubMed  CAS  Google Scholar 

  34. Lerman C, Croyle RT, Tercyak KP, Hamann H. Genetic testing: psychological aspects and implications. J Consult Clin Psychol. 2002;70:784–97.

    Article  PubMed  Google Scholar 

  35. Ropka ME, Wenzel J, Phillips EK, Siadaty M, Philbrick JT. Uptake rates for breast cancer genetic testing: a systematic review. Cancer Epidemiol Biomark Prev. 2006;15:840–55.

    Article  Google Scholar 

  36. Pasacreta JV. Psychosocial issues associated with genetic testing for breast and ovarian cancer risk: an integrative review. Cancer Invest. 2003;21:588–623.

    Article  PubMed  Google Scholar 

  37. Ryan EL, Skinner CS. Risk beliefs and interest in counseling: focus-group interviews among first-degree relatives of breast cancer patients. J Cancer Educ. 1999;14:99–103.

    PubMed  CAS  Google Scholar 

  38. Gil F, Méndez I, Sirgo A, Llort G, Blanco I, Cortés-Funes H. Perception of breast cancer risk and surveillance behaviours of women with family history of breast cancer: a brief report on a Spanish cohort. Psychooncology. 2003;12:821–7.

    Article  PubMed  Google Scholar 

  39. Schlich-Bakker KJ, ten Kroode HF, Ausems MG. A literature review of the psychological impact of genetic testing on breast cancer patients. Patient Educ Couns. 2006;62:13–20.

    Article  PubMed  Google Scholar 

  40. McAllister M, Davies L, Payne K, Nicholls S, Donnai D, MacLeod R. The emotional effects of genetic diseases: implications for clinical genetics. Am J Med Genet A. 2007;143A:2651–61.

    Article  PubMed  Google Scholar 

  41. Ando N, Iwamitsu Y, Kuranami M, Okazaki S, Yamamoto K, Watanabe M, et al. Concerns about inherited risk of breast cancer prior to diagnosis in Japanese patients with breast complaints. Fam Cancer. 2011;10:681–9.

    Article  PubMed  Google Scholar 

  42. Ritvo P, Edwards SA, Glendon G, Mirea L, Knight JA, Andrulis IL, et al. Beliefs about optimal age and screening frequency predict breast screening adherence in a prospective study of female relatives from the Ontario site of the Breast Cancer Family Registry. BMC Public Health. 2012;12:518.

    Article  PubMed  PubMed Central  Google Scholar 

  43. Matloff ET, Moyer A, Shannon KM, Niendorf KB, Col NF. Healthy women with a family history of breast cancer: impact of a tailored genetic counseling intervention on risk perception, knowledge, and menopausal therapy decision making. J Womens Health (Larchmt). 2006;15(7):843–56.

    Article  Google Scholar 

  44. Ardern-Jones A, Kenen R, Eeles R. Too much too soon? Patientsʼ and health professionalsʼ views concerning the impact of genetic testing at the time of breast cancer diagnosis in women under the age of 40. Eur J Cancer Care. 2005;14:272–81.

    Article  CAS  Google Scholar 

  45. Schwartz MD, Lerman C, Brogan B, Peshkin BN, Hughes Halbert C, DeMarco T, et al. Impact of BRCA1/2 counseling and testing on newly diagnosed breast cancer patients. J Clin Oncol. 2004;22:1823–9.

    Article  PubMed  Google Scholar 

  46. Schwartz MD, Lerman C, Brogan B, Peshkin BN, Isaacs C, DeMarco T, et al. Utilization of BRCA1/BRCA2 mutation testing in newly diagnosed breast cancer patients. Cancer Epidemiol Biomarkers Prev. 2005;14:1003–7.

    Article  PubMed  CAS  Google Scholar 

  47. Tercyak KP, Peshkin BN, Brogan BM, DeMarco T, Pennanen MF, Willey SC, et al. Quality of life after contralateral prophylactic mastectomy in newly diagnosed high-risk breast cancer patients who underwent BRCA1/2 gene testing. J Clin Oncol. 2007;25:285–91.

    Article  PubMed  Google Scholar 

  48. Schlich-Bakker KJ, Wárlám-Rodenhuis CC, van Echtelt J, van den Bout J, Ausems MG, ten Kroode HF. Short-term psychological distress in patients actively approached for genetic counselling after diagnosis of breast cancer. Eur J Cancer. 2006;42:2722–8.

    Article  PubMed  Google Scholar 

  49. Meiser B, Gleeson M, Watts K, Peate M, Zilliacus E, Barlow-Stewart K, et al. Getting to the point: what women newly diagnosed with breast cancer want to know about treatment-focused genetic testing. Oncol Nurs Forum. 2012;39:E101–11.

    Article  PubMed  Google Scholar 

  50. Wevers MR, Ausems MG, Verhoef S, Bleiker EM, Hahn DE, Hogervorst FB, et al. Behavioral and psychosocial effects of rapid genetic counseling and testing in newly diagnosed breast cancer patients: design of a multicenter randomized clinical trial. BMC Cancer. 2011;11:6.

    Article  PubMed  PubMed Central  Google Scholar 

  51. McGuire AL, Diaz CM, Wang T, Hilsenbeck SG. Social networkers’ attitudes toward direct-to-consumer personal genome testing. Am J Bioeth. 2009;9(6–7):3–10. doi:10.1080/15265160902928209.

    Article  PubMed  PubMed Central  Google Scholar 

  52. James KM, Cowl CT, Tilburt JC, Sinicrope PS, Robinson ME, Frimannsdottir KR, et al. Impact of direct-to-consumer predictive genomic testing on risk perception and worry among patients receiving routine care in a preventive health clinic. Mayo Clin Proc. 2011;86:933–40.

    Article  PubMed  PubMed Central  Google Scholar 

  53. Wakefield CE, Ratnayake P, Meiser B, Suthers G, Price MA, Duffy J, et al. “For all my family’s sake, I should go and find out”: an Australian report on genetic counseling and testing uptake in individuals at high risk of breast and/or ovarian cancer. Genet Test Mol Biomarkers. 2011;15:379–85.

    Article  PubMed  Google Scholar 

  54. Morgan D, Sylvester H, Lucas FL, Miesfeldt S. Cancer prevention and screening practices among women at risk for hereditary breast and ovarian cancer after genetic counseling in the community setting. Fam Cancer. 2009;8:277–87.

    Article  PubMed  CAS  Google Scholar 

  55. Brain K, Gray J, Norman P, Parsons E, Clarke A, Rogers C, et al. Why do women attend familial breast cancer clinics? J Med Genet. 2000;37:197–202.

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  56. Fraser L, Bramald S, Chapman C, Chu C, Cornelius V, Douglas F, et al. What motivates interest in attending a familial cancer genetics clinic? Fam Cancer. 2003;2:159–68.

    Article  PubMed  CAS  Google Scholar 

  57. Pal T, Rocchio E, Garcia A, Rivers D, Vadaparampil S. Recruitment of black women for a study of inherited breast cancer using a cancer registry-based approach. Genet Test Mol Biomarkers. 2011;15:69–77.

    Article  PubMed  Google Scholar 

  58. Rolnick SJ, Rahm AK, Jackson JM, Nekhlyudov L, Goddard KA, Field T, et al. Barriers in identification and referral to genetic counseling for familial cancer risk: the perspective of genetic service providers. J Genet Couns. 2011;20:314–22.

    Article  PubMed  Google Scholar 

  59. Anderson B, McLosky J, Wasilevich E, Lyon-Callo S, Duquette D, Copeland G. Barriers and facilitators for utilization of genetic counseling and risk assessment services in young female breast cancer survivors. J Cancer Epidemiol. 2012;2012:298745. doi:10.1155/2012/298745.

    Article  PubMed  PubMed Central  Google Scholar 

  60. Katapodi MC, Northouse L, Pierce P, Milliron KJ, Liu G, Merajver SD. Differences between women who pursued genetic testing for hereditary breast and ovarian cancer and their at-risk relatives who did not. Oncol Nurs Forum. 2011;38:572–81.

    Article  PubMed  Google Scholar 

  61. Armstrong K, Micco E, Carney A, Stopfer J, Putt M. Racial differences in the use of BRCA1/2 testing among women with a family history of breast or ovarian cancer. JAMA. 2005;293:1729–36.

    Article  PubMed  CAS  Google Scholar 

  62. Susswein LR, Skrzynia C, Lange LA, Booker JK, Graham ML 3rd, Evans JP. Increased uptake of BRCA1/2 genetic testing among African American women with a recent diagnosis of breast cancer. J Clin Oncol. 2008;26:32–6.

    Article  PubMed  Google Scholar 

  63. Chin TM, Tan SH, Lim SE, Iau P, Yong WP, Wong SW, et al. Acceptance, motivators, and barriers in attending breast cancer genetic counseling in Asians. Cancer Detect Prev. 2005;29:412–8.

    Article  PubMed  Google Scholar 

  64. Yoon SY, Thong MK, Taib NA, Yip CH, Teo SH. Genetic counseling for patients and families with hereditary breast and ovarian cancer in a developing Asian country: an observational descriptive study. Fam Cancer. 2011;10:199–205.

    Article  PubMed  Google Scholar 

  65. Genetic Information Non-Discrimination Act of 2008. H.R. 493, 110th Cong; 2007–2008.

  66. Sweet KM, Bradley TL, Westman JA. Identification and referral of families at high risk for cancer susceptibility. J Clin Oncol. 2002;20(2):528–37.

    Article  PubMed  Google Scholar 

  67. Bando H, Shimizu C, Yamamoto S, Mizota Y, Katou T. Current situation survey on provision of information about hereditary breast cancer by Japanese physician to young breast cancer patients [abstract] J Japan Soc. Clin Oncol. 2011;452:MS1–6.

    Google Scholar 

  68. Sugano K, Nakamura S, Ando J, Takayama S, Kamata H, Sekiguchi I, et al. Cross-sectional analysis of germline BRCA1 and BRCA2 mutations in Japanese patients suspected to have hereditary breast/ovarian cancer. Cancer Sci. 2008;99:1967–76.

    Article  PubMed  CAS  Google Scholar 

  69. Fostira F, Tsitlaidou M, Papadimitriou C, Pertesi M, Timotheadou E, Stavropoulou AV, et al. Prevalence of BRCA1 mutations among 403 women with triple-negative breast cancer: implications for genetic screening selection criteria: a Hellenic Cooperative Oncology Group Study. Breast Cancer Res Treat. 2012;134:353–62.

    Article  PubMed  CAS  Google Scholar 

  70. “Guidelines for Genetic Tests and Diagnoses in Medical Practice” The Japanese Association of Medical Sciences. http://jams.med.or.jp/.

Download references

Acknowledgments

I thank Brian K. Purdue for his native speaker revision. I am particularly grateful for the insightful and constructive comments given by Dr. Emiko Noguchi from the University of Tsukuba.

Conflict of interest

Hiroko Bando has no conflict of interest.

Author information

Authors and Affiliations

  1. Department of Breast and Endocrine Surgery, Faculty of Medicine, University of Tsukuba, 1-1-1 Tennodai, Tsukuba, Ibaraki, 305-8575, Japan

    Hiroko Bando

Authors
  1. Hiroko Bando
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Hiroko Bando.

About this article

Cite this article

Bando, H. Issues of concern in risk assessment, genetic counseling, and genetic testing of younger breast cancer patients in Japan. Breast Cancer 21, 656–663 (2014). https://doi.org/10.1007/s12282-013-0477-z

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12282-013-0477-z

Keywords

Search

Navigation